Published in Case Rep Cardiol on March 15, 2016
Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention (2015) 4.00
1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet (2016) 2.68
Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation (2011) 2.20
Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis. JACC Cardiovasc Interv (2016) 1.76
[A new classification of coronary bifurcation lesions]. Rev Esp Cardiol (2006) 1.44
Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European Bifurcation Club meetings. EuroIntervention (2014) 1.24
Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions. J Am Coll Cardiol (2000) 1.12
Bifurcation Optimisation Stent System (BiOSS Lim) with sirolimus elution: results from porcine coronary artery model. EuroIntervention (2011) 0.83
Drug-eluting stents in bifurcations: bench study of strut deformation and coating lesions. Circ Cardiovasc Interv (2010) 0.83
Culotte stenting with bioabsorbable everolimus-eluting stents. Int J Cardiol (2013) 0.82